Ventyx posts phase 2 Parkinson's data ahead of potential talks with Sanofi

Ventyx Biosciences has shared phase 2a data on a Parkinson’s disease prospect that has caught the eye of Sanofi. The readout shows the effect of VTX3232 on biomarkers, providing some of the data that will inform whether Sanofi takes up its right of first negotiation on the NLRP3 inhibitor.

Jun 17, 2025 - 15:00
 0
Ventyx posts phase 2 Parkinson's data ahead of potential talks with Sanofi
Ventyx Biosciences has shared phase 2a data on a Parkinson’s disease prospect that has caught the eye of Sanofi. The readout shows the effect of VTX3232 on biomarkers, providing some of the data that will inform whether Sanofi takes up its right of first negotiation on the NLRP3 inhibitor.